References
- Bamford C, Bonorchis K, Elliott E, et al. Antimicrobial susceptibility patterns of selected bacteraemic isolates from public sector hospitals in South Africa. South Afr J Epidemiol Infect. 2009;24(2):28–30
- Brink A, Feldman C, Richards G, et al. Emergence of extensive drug resistance (XDR)among Gram-negative bacilli in South Africa looms nearer. SAMJ. 2008;98(8):585–592.
- Martinez JA, Aguilar J, Almela M, et al. Prior use of carbapenems may be a significantrisk factor for extended-spectrum B-lactamase producing Escherichia coli or Klebsiella pneumoniae in patients with bacteremia. J Antimicrob Chemother. 2006;58(5):1082–1085.
- Elliott E, Brink A, van Greunen J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum B-lactamase. Clin Infect Dis. 2006:42(11):e95–e98.
- BrinkA, Coetzee J, Clay C, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Micro. Published ahead of print, November 2011.
- Woodford N, et al. Comparison of BD Phoenix, Vitek 2, and Microscan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J Clin Micro. 2010;48(8):2999–3002.
- Thomson K. Extended-spectrum-B-lactamase, AmpC, and carbapenemase issues. J Clin Micro. 2010;48(4):1019–1025.
- Ho PL, Lo WU, Yeung MK, et al. Complete sequencing of pNDM-HK Encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coil strain isolated in Hong Kong. PLoS One. 2011;6(3):e17989.
- Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: Extended-spectrum B-lactamase producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multi-drug resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250–259.